GWPH News and Press, GW Pharmaceuticals Plc From 11/29/20

Should cannabis investors be buying stocks in the tobacco sector? Is now a good time to invest in pot stocks? How long should investors hold their pot stocks? These are just a few of the questions we ask Meb Faber, CEO and CIO of Cambria Investment Management. The Motley Fool sat down w...

Cannabis investors have seen several cycles of hype and disappointment over the years. But quantitative investors are eyeing some opportunities in the sector today. The Motley Fool sat down with Meb Faber, CEO and CIO of Cambria Investment Management, to talk about Cambria Cannabis ET...

Should cannabis investors be buying stocks in the tobacco sector? Is now a good time to invest in pot stocks? How long should investors hold their pot stocks? These are just a few of the questions we ask Meb Faber, CEO and CIO of Cambria Investment Management. The Motley Fool sat down w...

Are You A Fan Of These CBD Marijuana Stocks? It seems as though when investors speak about marijuana stocks they often mention pure-play or MSO pot stocks . This because most of the big players fall under these categories. Focusing on the top marijuana stocks to buy isn ...

GW Pharmaceuticals plc (GWPH) Stifel Virtual Healthcare Conference November 18, 2020 1:20 PM ET Company Participants Justin Gover - CEO & Executive Director Darren Cline - U.S. Chief Commercial Officer Conference Call Participants Paul Matteis - Stifel Presentation Operator Paul Matteis G...

ATLANTA, GA / ACCESSWIRE / November 17, 2020 / Findit, Inc. (OTC PINK: FDIT ) owner of Findit.com , a full-service social networking platform which provides online marketing campaigns and tools for members to increase brand awareness through content creation and sharing, resulting in indexi...

During a recessionary environment is historically when VCs make a ton of money. Narbe Alexandrian, President and CEO of Canopy Rivers, the venture capital arm of Canopy Growth, returns to the show. We discuss its portfolio, TerrAscend capitalizing on New Jersey going legal, and bu...

- Results from analysis of three P hase 3 clinical studies showed statistically significant improvement in spasticity in people with multiple sclerosis - Treatment with nabiximols seen in this analysis was not associated with increased muscle weakness or a notable ch...

Curaleaf has operations in 14 states, some of which just expanded their cannabis offerings via legislation. Future projections for cannabis in the United States projected to $35B and a Biden win would help ensure that goal achieved; Curaleaf last quarter hits break-even with a bea...

Zogenix just launched Fintepla, a product to treat Dravet syndrome. GW Pharma already has a Fintepla competitor Epidiolex approved and growing big sales in Dravet syndrome and other indications that Fintepla will likely expand to. Zogenix’s major sell-off makes its valuatio...